They started as diabetes medications. Then something unexpected happened: patients taking GLP-1 receptor agonist drugs like semaglutide — marketed as Ozempic for diabetes and Wegovy for weight loss — began losing significant amounts of weight. Word spread rapidly.
By 2023, demand for these drugs had far outpaced supply. 'Ozempic' became a household word. Celebrities discussed their use openly. The cultural conversation about body weight, obesity, and medical intervention was fundamentally shifted.
The Medical Reality
The drugs work. Clinical trials showed average weight loss of 15-20% of body weight, with some patients losing significantly more. For many people with obesity — a condition with serious health consequences — the drugs represented a genuine medical breakthrough.
The Broader Conversation
The widespread adoption of weight loss drugs also prompted complex conversations about body image, the medicalization of weight, access and equity (the drugs are expensive and not universally covered by insurance), and what the drugs' side effects meant for long-term use.
Medical breakthroughs change how we understand the body. This one changed the conversation for millions of people.